Bernd Benninghoff

ORCID: 0000-0003-1264-7074
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Viral gastroenteritis research and epidemiology
  • Hepatitis Viruses Studies and Epidemiology
  • Viral Infections and Immunology Research
  • Animal Virus Infections Studies
  • Nonmelanoma Skin Cancer Studies
  • Immunotherapy and Immune Responses
  • Vaccine Coverage and Hesitancy
  • Immune Response and Inflammation
  • Algal biology and biofuel production
  • RNA Interference and Gene Delivery
  • Respiratory viral infections research
  • Cervical Cancer and HPV Research
  • Lipid Membrane Structure and Behavior
  • Congenital Anomalies and Fetal Surgery
  • Inflammatory mediators and NSAID effects
  • Cancer and Skin Lesions
  • Influenza Virus Research Studies
  • Amino Acid Enzymes and Metabolism
  • Peroxisome Proliferator-Activated Receptors
  • Eicosanoids and Hypertension Pharmacology
  • Virus-based gene therapy research
  • T-cell and Retrovirus Studies
  • Dermatology and Skin Diseases
  • Medicinal Plants and Bioactive Compounds
  • Sulfur Compounds in Biology

GlaxoSmithKline (Belgium)
2014-2025

German Cancer Research Center
1988-2015

Institute of Immunology
1990-2015

Heidelberg University
1991-2015

University of Duisburg-Essen
2005

Helmholtz Centre for Infection Research
2005

University of Basel
2005

University of Münster
2005

3M (Germany)
2004-2005

Kiel University
2001

Background: The incidence of nonmelanoma skin cancer, basal cell carcinomas (BCCs), and squamous (SCCs) is increasing, representing a major medical economic problem. Imiquimod, topical small-molecule immune response modifier, has shown efficacy toward BCC actinic keratoses in clinical trials. Imiquimod acts both indirectly, via cytokine-mediated stimulation cellular responses, directly, through unknown mechanisms against tumor cells. We examined the mechanism by which imiquimod induces...

10.1093/jnci/djg016 article EN JNCI Journal of the National Cancer Institute 2003-08-05

<h3>Background</h3> Imiquimod is a local immune response modifier that has demonstrated potent antiviral and antitumor activity. It enhances innate acquired responses via endogenous cytokine production proven efficacious in clearing superficial basal cell carcinoma (sBCC). <h3>Objective</h3> To evaluate the mechanisms by which topical imiquimod treatment leads to sBCC clearance vivo. <h3>Design</h3> A pilot, open-label, nonrandomized study. <h3>Setting</h3> Zurich, Switzerland....

10.1001/archderm.139.10.1325 article EN cc-by Archives of Dermatology 2003-10-01

Actinic keratoses (AK) are premalignant lesions, which routinely treated by destructive procedures such as cryotherapy, electrodessication or topical 5-fluorouracil.The aim of this study is to report six cases AK with a potential new therapy, imiquimod.Subjects included in had suffered recurrent for between 5 and 16 years. All men were imiquimod 5% cream three times week 6-8 weeks. In the event local skin reaction treatment was modified two per week.All lesions successfully cleared after...

10.1046/j.1365-2133.2001.04197.x article EN British Journal of Dermatology 2001-05-01

Human rTNF-alpha stimulates the metabolism of murine peritoneal macrophages as demonstrated by an increased consumption arginine and release L-ornithine. This TNF-mediated effect is augmented several substances that raise intracellular concentration cAMP, including PGE2, cholera toxin, dibutyryl-cAMP. TNF also endogenous production PGE2 in cultures macrophages. The addition cyclo-oxygenase inhibitor, indomethacin, suppresses metabolic activation macrophages, this suppressive indomethacin...

10.4049/jimmunol.141.2.587 article EN The Journal of Immunology 1988-07-15

Variability in rotavirus gastroenteritis (RVGE) epidemiology can influence the optimal vaccination schedule. We evaluated regional trends age of RVGE episodes low- to middle- versus high-income countries three continents. undertook a post-hoc analysis based on efficacy trials human vaccine (HRV; Rotarix™, GSK Vaccines), which 1348, 1641, and 5250 healthy infants received placebo Europe (NCT00140686), Africa (NCT00241644), Asia (NCT00197210, NCT00329745). Incidence any/severe by at onset was...

10.1080/21645515.2016.1179412 article EN cc-by Human Vaccines & Immunotherapeutics 2016-06-03

Abstract Background Imiquimod, a potent immunomodulator, not having direct antiproliferative activity, was found to be effective in genital and cutaneous premalignancies malignancies. As tumor development depends on blood vessel supply, the inhibition of angiogenesis could responsible for antitumor activity. Objective To find murine model whether imiquimod has antiangiogenic activity this is mediated by locally induced cytokines. Methods The study performed two cell lines: Skv human...

10.1111/j.1365-4632.2004.02318.x article EN International Journal of Dermatology 2004-12-23

A controversy exists about the potential effect of childhood varicella vaccination on Herpes Zoster (HZ) incidence. Mathematical models projected temporary HZ incidence increase after vaccine introduction that was not confirmed by real-world evidence. These assume absence contacts with infected children would prevent exogenous boosting Varicella-Zoster-Virus (VZV) immunity and they do include an endogenous VZV immunity-boosting mechanism following asymptomatic reactivation. This study aims...

10.1186/s12879-019-3759-z article EN cc-by BMC Infectious Diseases 2019-02-06

Background: Bivalent human papillomavirus HPV16/18-AS04 vaccine (Cervarix, GSK) offers direct protection against HPV16/18. Results from randomised controlled trials showed cross protective effects and suggested that declines in some closely related HPV types could be expected a population with high vaccination coverage. Aim: To evaluate the evidence for cross-protection afforded by post-implementation surveillance England, how this complements clinical trial data observations other...

10.1016/j.vaccine.2024.126215 article EN cc-by Vaccine 2024-08-29

Imiquimod represents a synthetic local immune response modifier that has demonstrated efficacy in clearing basal cell carcinoma. Via interaction with Toll-like receptor 7 on cells, imiquimod induces production of cytokines, such as interferon (IFN)-alpha.To more closely define and elucidate mechanisms leading to carcinoma clearance vivo, we examined gene expression profiles skin before after treatment 5% cream (Aldara) by using high-density oligonucleotide arrays.We show predominantly genes...

10.1158/1078-0432.ccr-04-0193 article EN Clinical Cancer Research 2004-08-01

Actinic keratoses (AKs) are premalignant lesions that can progress into squamous cell carcinoma. Imiquimod, which belongs to the new class of immune-response modifiers, was recently shown be effective in treatment AKs. The underlying mechanisms not fully understood.To study expression individual genes uninvolved skin and AKs before therapy elucidate way these is influenced by imiquimod therapy.We treated 13 patients with AK compared gene before, during (five patients) after (eight skin. We...

10.1111/j.1365-2133.2004.06236.x article EN British Journal of Dermatology 2004-12-01

Despite successful infant vaccination programmes, pertussis remains endemic in many countries. Waning immunity leaves adolescents and adults susceptible to disease potential reservoirs of infection allowing transmission vulnerable infants. Misdiagnosis leads significant underestimation burden inappropriate treatment. This online survey 517 European health care professionals (HCP) examined their knowledge, attitudes practices regarding adult vaccination. Compared with other...

10.4161/hv.7.2.13918 article EN Human Vaccines 2011-02-01

An online survey was designed to assess awareness and understanding of Rotavirus (RV) gastroenteritis (RVGE), knowledge attitudes towards RV vaccination in Germany, Poland, Turkey, Indonesia, the Philippines Thailand. Survey participants (n = 1500) comprised parents, expectant parents guardians children ≤5 years age who have sole or joint responsibility for health well-being decisions relating their child, were recruited from an panel provided consent study participation. Participants most...

10.1080/21645515.2019.1632685 article EN cc-by Human Vaccines & Immunotherapeutics 2019-06-18

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has pushed many healthcare systems into crisis. High vaccine coverage amongst children reduces emergency room presentations, hospital admissions and deaths due to vaccine-preventable diseases, freeing up resources including polymerase chain reaction testing for patients with SARS-CoV-2. In Europe, rotavirus gastroenteritis leads 75,000–150,000 hospitalisations 600,000 medical encounters annually. Nevertheless, in 2022,...

10.1007/s40121-022-00697-7 article EN cc-by-nc Infectious Diseases and Therapy 2022-11-10
Coming Soon ...